Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

Phase 1 Completed 4 enrolled AstraZeneca

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.

Timeline

Start: 2008-02
Primary completion: 2008-07
Completion: 2008-07

Publications

Jucaite A, Cselenyi Z, Lappalainen J, McCarthy DJ, Lee CM, Nyberg S, Varnas K, Stenkrona P, Halldin C, Cross A, Farde L. GABAA receptor occupancy by subtype selective GABAAalpha2,3 modulators: PET studies in humans. Psychopharmacology (Berl). 2017 Feb;234(4):707-716. doi: 10.1007/s00213-016-4506-4. Epub 2016 Dec 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD7325	Small molecule	0.2 mg	Oral
Subject	AZD7325	Small molecule	30 mg	Oral
Background	Flumazenil	Small molecule	—	Intravenous

Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

Summary

Timeline

Publications

Drugs

Indications